Eli Lilly (LLY)
(Delayed Data from NYSE)
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
3 Large Drug Stocks That Have Outperformed Industry YTD
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
by Zacks Equity Research
Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, Accenture & The TJX Companies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).
Novo Nordisk (NVO) to Expand Manufacturing Site in France
by Zacks Equity Research
Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.
Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More
by Kinjel Shah
Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.
Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
ABBV vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABBV vs. LLY: Which Stock Is the Better Value Option?
Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWB
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
by Zacks Equity Research
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Billionaires Bullish on Big Tech: ETFs in Focus
by Sanghamitra Saha
The latest 13-F filings of billionaires indicate that most are still bullish on big techs.
13F Rundown: Tepper, Buffett, Druckenmiller
by Andrew Rocco
Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.
Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GSEW
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
by Zacks Equity Research
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
by Zacks Equity Research
Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
4 Large Drug Stocks Likely to Sail Through Industry Woes
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
by Zacks Equity Research
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.